Granza Bio is a biotech startup developing a delivery “shell” platform to direct immunotherapy and  attack particles to various body parts and specific tissues. The company secured $7 million in funding  from Felicis and Refactor. The funding round saw participation from Granza’s existing investors  including Y Combinator. The startup plans to use these fresh proceeds to expand its biotech research  and advance cancer treatment delivery technologies. 

The co-founder of Granza Bio, Nandakumar mentioned that they initially planned to raise $2.6 million and use it on a very important experiment. However, the increased interest of investors allowed them  to raise a bigger round that would enable the firm to expand its biotech research. On Wednesday the  startup announced the closing of this seed funding round at $7.5 million. The partner at Felicis, Tobi  Coker told TechCrunch in an interview that the Granza Bio’s mission perfectly matches the thesis of  Felicis that saysto treat cancers and autoimmune diseases body’simmune system should be activated. 

Felicis is a venture capital firm known for investing in early-stage startups including Cruise, Canva,  Flexport, and Shopify. This VC firm has invested in over 15 percent of biology-based startups like  Recursion Pharmaceuticals. The investors of Granza Bio believe that the firm will develop a therapeutic  cargo delivery system to help develop a whole new host of new drugs. The investment shows the trust  of investors in the firm’s market potential and business model. 

This biotech company develops a novel delivery ”Shell” platform and innovative solutions in therapy,  diagnostics, and medical devices. The startup is developing “attack particles” to only target cancer cells  while preventing side effects and unwanted toxicity. These particles showed cancer cell-killing properties in the brain, lungs, ovarian, and skin cancers. This is not only limited to cancer treatment  but it can also treat autoimmune infections and diseases. The startup intends to use a portion of this  investment to expand operations and develop advanced technologies.  

Conclusion: 

Biotechnology company Granza Bio secured $7 million in its seed funding round led by Refcator and  Felicis. The round saw participation from various new and existing investors including Y Combinator.  The startup plans to use these fresh proceeds to expand its biotech research and advance cancer  treatment delivery technologies. The company is currently working on developing a delivery “shell”  platform to direct immunotherapy and attack particles to various body parts and specific tissues and  treat cancer cells. The startup initially planned to raise $2.6 million but the increased interest of  investors led to a bigger round of $7 million. Felicis is a venture capital company that invested in around  15 percent of biology-focused startups and it is known to make early bets on growing startups. This  biotech company develops a novel delivery ”Shell” platform and innovative solutions in therapy,  diagnostics, and medical devices. The investors of the startup believe that the firm will develop a  therapeutic cargo delivery system to treat a host of new drugs